Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer
Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). In this study, w...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.974487/full |
| _version_ | 1797988913029054464 |
|---|---|
| author | Xinyi Yang Xinyi Yang Desheng Weng Desheng Weng Qiuzhong Pan Qiuzhong Pan Tong Xiang Tong Xiang Chaopin Yang Chaopin Yang Zhengrong Wu Minxing Li Minxing Li Songzuo Xie Songzuo Xie Yan Tang Yan Tang Jianchuan Xia Jianchuan Xia Jingjing Zhao Jingjing Zhao |
| author_facet | Xinyi Yang Xinyi Yang Desheng Weng Desheng Weng Qiuzhong Pan Qiuzhong Pan Tong Xiang Tong Xiang Chaopin Yang Chaopin Yang Zhengrong Wu Minxing Li Minxing Li Songzuo Xie Songzuo Xie Yan Tang Yan Tang Jianchuan Xia Jianchuan Xia Jingjing Zhao Jingjing Zhao |
| author_sort | Xinyi Yang |
| collection | DOAJ |
| description | Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). In this study, we investigated adjuvant cellular immunotherapy (CIT) in patients with post-mastectomy breast cancer. We enrolled 214 post-mastectomy breast cancer patients, including 107 patients in the control group (who received chemotherapy/radiotherapy/endocrine therapy) and the other 107 patients in the CIT group (who received chemotherapy/radiotherapy/endocrine therapy and subsequent immune cell infusion). Of these 214 patients, 54 had TNBC, including 26 patients in the control group and 28 patients in the CIT group. Survival analysis showed that the overall survival rate of patients treated with cellular immunotherapy was higher than that of patients who were not treated with CIT. Compared to those who received cytokine-induced killer (CIK) cells alone, the patients who received CIK combined with natural killer (NK) cell immunotherapy showed the best overall survival rate. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients in the TNBC subgroup and the patients who were aged over 50 years. Our study indicates that adjuvant CIK cell combined with NK cell treatment is an effective therapeutic strategy to prolong the survival of post-mastectomy patients, particularly for TNBC patients and those who are aged over 50 years. |
| first_indexed | 2024-04-11T08:11:42Z |
| format | Article |
| id | doaj.art-843cb2cabc0e4e54b69940a8196f7b3a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T08:11:42Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-843cb2cabc0e4e54b69940a8196f7b3a2022-12-22T04:35:21ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-11-011310.3389/fimmu.2022.974487974487Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancerXinyi Yang0Xinyi Yang1Desheng Weng2Desheng Weng3Qiuzhong Pan4Qiuzhong Pan5Tong Xiang6Tong Xiang7Chaopin Yang8Chaopin Yang9Zhengrong Wu10Minxing Li11Minxing Li12Songzuo Xie13Songzuo Xie14Yan Tang15Yan Tang16Jianchuan Xia17Jianchuan Xia18Jingjing Zhao19Jingjing Zhao20Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaBreast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). In this study, we investigated adjuvant cellular immunotherapy (CIT) in patients with post-mastectomy breast cancer. We enrolled 214 post-mastectomy breast cancer patients, including 107 patients in the control group (who received chemotherapy/radiotherapy/endocrine therapy) and the other 107 patients in the CIT group (who received chemotherapy/radiotherapy/endocrine therapy and subsequent immune cell infusion). Of these 214 patients, 54 had TNBC, including 26 patients in the control group and 28 patients in the CIT group. Survival analysis showed that the overall survival rate of patients treated with cellular immunotherapy was higher than that of patients who were not treated with CIT. Compared to those who received cytokine-induced killer (CIK) cells alone, the patients who received CIK combined with natural killer (NK) cell immunotherapy showed the best overall survival rate. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients in the TNBC subgroup and the patients who were aged over 50 years. Our study indicates that adjuvant CIK cell combined with NK cell treatment is an effective therapeutic strategy to prolong the survival of post-mastectomy patients, particularly for TNBC patients and those who are aged over 50 years.https://www.frontiersin.org/articles/10.3389/fimmu.2022.974487/fulladjuvant cellular immunotherapybreast cancernatural killer cellsprognosiscytokine-induced killer |
| spellingShingle | Xinyi Yang Xinyi Yang Desheng Weng Desheng Weng Qiuzhong Pan Qiuzhong Pan Tong Xiang Tong Xiang Chaopin Yang Chaopin Yang Zhengrong Wu Minxing Li Minxing Li Songzuo Xie Songzuo Xie Yan Tang Yan Tang Jianchuan Xia Jianchuan Xia Jingjing Zhao Jingjing Zhao Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer Frontiers in Immunology adjuvant cellular immunotherapy breast cancer natural killer cells prognosis cytokine-induced killer |
| title | Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer |
| title_full | Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer |
| title_fullStr | Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer |
| title_full_unstemmed | Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer |
| title_short | Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer |
| title_sort | adjuvant alternative cytokine induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post mastectomy breast cancer |
| topic | adjuvant cellular immunotherapy breast cancer natural killer cells prognosis cytokine-induced killer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.974487/full |
| work_keys_str_mv | AT xinyiyang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT xinyiyang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT deshengweng adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT deshengweng adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT qiuzhongpan adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT qiuzhongpan adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT tongxiang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT tongxiang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT chaopinyang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT chaopinyang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT zhengrongwu adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT minxingli adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT minxingli adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT songzuoxie adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT songzuoxie adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT yantang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT yantang adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT jianchuanxia adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT jianchuanxia adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT jingjingzhao adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer AT jingjingzhao adjuvantalternativecytokineinducedkillercellcombinedwithnaturalkillercellimmunotherapyimprovestheprognosisofpostmastectomybreastcancer |